Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | PHGDH | O43175 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2643465 | 0.78 | RXFP1 (0.60) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL3593923 | 0.76 | RXFP1 (0.54) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL9040651 | 0.75 | PSEN1 (0.47) | OXER1HDAC1 | |
| SCHEMBL17324809 | 0.75 | RXFP1 (0.64) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL43328 | 0.75 | KDM4E (0.66) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL2643531 | 0.75 | CCR2 (0.59) | — | |
| SCHEMBL721418 | 0.75 | GCGR (0.57) | — | |
| SCHEMBL13415456 | 0.74 | RXFP1 (0.62) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL1253237 | 0.74 | RXFP1 (0.56) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL23112798 | 0.73 | HSD17B3 (0.55) | HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-7598398-B2 | Acyl indoles, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20070088071-A1 | Acyl indoles, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | RXFP1 3336/4885OXER1 2109/4885HDAC3 135/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | RXFP1 3336/4885OXER1 2109/4885HDAC3 135/4885 |
| US-20070088071-A1 | Acyl indoles, compositions containing such compounds and methods of use | GPR119, IAPP, GLP1R | RXFP1 298/4885OXER1 1021/4885HDAC3 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.